Target Values of Blood Pressure in Patients with Diabetes Mellitus

Czech version

Authors: M. Souček
Authors‘ workplace: II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.
Published in: Vnitř Lék 2009; 55(4): 363-367
Category:

Overview

Diabetes mellitus considerably worsens the prognosis of hypertension both in the occurrence of microvascular and macrovascular complications. The guidelines of the European Society of Hypertension and the European Society of Cardiology suggest a significantly more invasive treatment of hypertension achieving blood pressure target values below 130/80 mm Hg. The control of hypertension in diabetic patients treated with antihypertensives in the consulting rooms of our physicians is poor. Target values < 130/80 mm Hg are achieved in less than 5% of cases. More extensive application of combined treatment, in particular 3 or more antihypertensives, and improvement of patients’ adherence to the treatment could improve the current situation.

Key words:
hypertension – diabetes mellitus – hypertension control with diabetes – cardiovascular risk

Sources

1. Rathmann W, Giani G. Global prevalence of diabetes: estimates for the year 2000 and projection for 2030. Diabetes Care 2004; 27: 1047–1053.

2. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professional from the American Heart Association. Circulation 1999; 100: 1134–1346.

3. Wilson PW, D’Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.

4. Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988; 11: 821–827.

5. Sowers JR, Farrow SL. Treatment of elderly hypertensive patients with diabetes, renal disease and coronary heart disease. Am J Geriatr Cardiol 1996; 5: 57–70.

6. Cífková R. Léčba hypertenze u pacientů s diabetem. Farmakoterapie 2008; 3: 303–308.

7. Mancia G, De Backer C, Dominiczak A et al. 2007 Guidelines for management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–1187.

8. Widimský J jr, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2007. Doporučení české společnosti pro hypertenzi. Cor Vasa 2008; 50: K5–K22.

9. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403–418.

10. Tarnow L, Rossing P, Gall MA et al. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994; 17: 1247–1251.

11. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistence and the sympathoadrenal system. N Engl J Med 1996; 334: 374–381.

12. Grossmann E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med 1996; 125: 304–310.

13. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non‑insulin‑dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413–1418.

14. Teuscher A, Schnell H, Wilson PW. Incidence of diabetic retinopathy and relationship to baseline plasma glukose and blood pressure. Diabetes Care 1988; 11: 246–251.

15. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin‑converting‑enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456–1462.

16. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin‑Dependent Diabetes Mellitus. Lancet 1998; 351: 28–31.

17. Borch-Johnson K, Nissen R, Nerup J. Blood pressure after 40 years of insulin dependent diabetes. Nephron 1985; 4: 11–12.

18. Hannson L, Zanchetti A, Carruthers SG et al. Effect of intensive blood-pressure lowering and low‑dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–1762.

19. Williams B. The pharmacological treatment of hypertension in diabetes. In: Williams B (ed). Hypertension in diabetes. London: Martin Dunitz 2003: 285–316.

20. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborating Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and mikrovascular outcomes in patients type 2 diabetes mellitus (the ADVANCE trial): a randomised controled trial. Lancet 2007; 370: 829–840.

21. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008; 358: 2630–2633.

22. Szabó M. Studie ADVANCE – větev intervence hyperglykémie. Remedia 2008; 4: 310–313.

23. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta‑analysis. Lancet 2007; 369: 201–207.

24. Kalita Z, Souček M, Sachová M. Výskyt rizikových faktorů cévní mozkové příhody v populaci České republiky. Průzkum STOP CMP. Prakt Lék 2003; 83: 643–646.

25. Widimský J, Souček M, Sachová M et al. Hypertenze a diabetes mellitus v ordinacích praktických lékařů. Výskyt hypertenze a její kontrola. Cor Vasa 2005; 47: 127–132.

26. Souček M, Widimsky J, Lánská V. Control of hypertension in patients with hypertension, diabetes, and impaired fasting glucose by Czech primary care physicians. Kidney Blood Press Res 2006; 29: 366–372.